Download MendeleyDiscovery of Orally Bioavailable Purine-Based Inhibitors of the Low-Molecular-Weight Protein Tyrosine Phosphatase.
Stanford, S.M., Diaz, M.A., Ardecky, R.J., Zou, J., Roosild, T., Holmes, Z.J., Nguyen, T.P., Hedrick, M.P., Rodiles, S., Guan, A., Grotegut, S., Santelli, E., Chung, T.D.Y., Jackson, M.R., Bottini, N., Pinkerton, A.B.(2021) J Med Chem 64: 5645-5653
- PubMed: 33914534
- DOI: https://doi.org/10.1021/acs.jmedchem.0c02126
- Primary Citation of Related Structures:
7KH8 - PubMed Abstract:
Obesity-associated insulin resistance plays a central role in the pathogenesis of type 2 diabetes. A promising approach to decrease insulin resistance in obesity is to inhibit the protein tyrosine phosphatases that negatively regulate insulin receptor signaling. The low-molecular-weight protein tyrosine phosphatase (LMPTP) acts as a critical promoter of insulin resistance in obesity by inhibiting phosphorylation of the liver insulin receptor activation motif. Here, we report development of a novel purine-based chemical series of LMPTP inhibitors. These compounds inhibit LMPTP with an uncompetitive mechanism and are highly selective for LMPTP over other protein tyrosine phosphatases. We also report the generation of a highly orally bioavailable purine-based analogue that reverses obesity-induced diabetes in mice.
Organizational Affiliation:
Department of Medicine, University of California, San Diego, La Jolla, California 92037, United States.
